Cargando…

Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes

Several immunotherapies have demonstrated endogenous insulin preservation in recent-onset type 1 diabetes (T1D). We considered the primary results of rituximab, abatacept, teplizumab, alefacept, high-dose antithymocyte globulin (ATG), low-dose ATG, and low-dose ATG ± granulocyte-colony–stimulating f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobsen, Laura M., Bundy, Brian N., Greco, Madison N., Schatz, Desmond A., Atkinson, Mark A., Brusko, Todd M., Mathews, Clayton E., Herold, Kevan C., Gitelman, Stephen E., Krischer, Jeffrey P., Haller, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2020
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757538/ https://www.ncbi.nlm.nih.gov/pubmed/32833543 http://dx.doi.org/10.1089/dia.2020.0305

Ejemplares similares

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA(1c), and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data
por: Haller, Michael J., et al.
Publicado: (2019)

2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes
por: Lin, Andrea, et al.
Publicado: (2018)

Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes
por: Xue, Song, et al.
Publicado: (2015)

Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes
por: Haller, Michael J., et al.
Publicado: (2016)

Acute Versus Progressive Onset of Diabetes in NOD Mice: Potential Implications for Therapeutic Interventions in Type 1 Diabetes
por: Mathews, Clayton E., et al.
Publicado: (2015)

A quantitative measure of treatment response in recent‐onset type 1 diabetes
por: Bundy, Brian N., et al.
Publicado: (2020)

Progressive Erosion of β-Cell Function Precedes the Onset of Hyperglycemia in the NOD Mouse Model of Type 1 Diabetes
por: Ize-Ludlow, Diego, et al.
Publicado: (2011)

Responders to low-dose ATG induce CD4(+) T cell exhaustion in type 1 diabetes
por: Jacobsen, Laura M., et al.
Publicado: (2023)

Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function
por: Herold, Kevan C., et al.
Publicado: (2023)

Application of a Genetic Risk Score to Racially Diverse Type 1 Diabetes Populations Demonstrates the Need for Diversity in Risk-Modeling
por: Perry, Daniel J., et al.
Publicado: (2018)

Type 1 Interferons Potentiate Human CD8(+) T-Cell Cytotoxicity Through a STAT4- and Granzyme B–Dependent Pathway
por: Newby, Brittney N., et al.
Publicado: (2017)

Autologous Umbilical Cord Blood Transfusion in Young Children With Type 1 Diabetes Fails to Preserve C-Peptide
por: Haller, Michael J., et al.
Publicado: (2011)

Improving the Prediction of Type 1 Diabetes Across Ancestries
por: Kaddis, John S., et al.
Publicado: (2022)

Human immune phenotyping reveals accelerated aging in type 1 diabetes
por: Shapiro, Melanie R., et al.
Publicado: (2023)

Influence of Membrane CD25 Stability on T Lymphocyte Activity: Implications for Immunoregulation
por: Brusko, Todd M., et al.
Publicado: (2009)

Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
por: Orban, Tihamer, et al.
Publicado: (2014)

Rituximab Selectively Suppresses Specific Islet Antibodies
por: Yu, Liping, et al.
Publicado: (2011)

Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes
por: Greenbaum, Carla J., et al.
Publicado: (2012)

Autologous Umbilical Cord Blood Transfusion in Very Young Children With Type 1 Diabetes
por: Haller, Michael J., et al.
Publicado: (2009)

Understanding Pre-Type 1 Diabetes: The Key to Prevention
por: Jacobsen, Laura M., et al.
Publicado: (2018)

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders
por: Herold, Kevan C., et al.
Publicado: (2013)

B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results
por: Pescovitz, Mark D., et al.
Publicado: (2014)

A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes
por: Herold, Kevan C., et al.
Publicado: (2005)

Response to Comment on: Greenbaum et al. Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes. Diabetes 2012;61:1323–1330
por: Greenbaum, Carla J., et al.
Publicado: (2012)

Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials
por: Kinney, Mara, et al.
Publicado: (2023)

Serum Trypsinogen Levels in Type 1 Diabetes
por: Li, Xia, et al.
Publicado: (2017)

Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials
por: Sosenko, Jay M., et al.
Publicado: (2020)

T Cell Receptor Profiling in Type 1 Diabetes
por: Jacobsen, Laura M., et al.
Publicado: (2017)

How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic?
por: Haller, Michael J., et al.
Publicado: (2021)

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association
por: Insel, Richard A., et al.
Publicado: (2015)

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protégé Trial
por: Hagopian, William, et al.
Publicado: (2013)

Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report
por: Wherrett, Diane K., et al.
Publicado: (2015)

Islet Autoantibody Seroconversion in the DPT-1 Study: Justification for repeat screening throughout childhood
por: Vehik, Kendra, et al.
Publicado: (2011)

Vitamin D Levels in Subjects With and Without Type 1 Diabetes Residing in a Solar Rich Environment
por: Bierschenk, Lindsey, et al.
Publicado: (2009)

Distribution of C-Peptide and Its Determinants in North American Children at Risk for Type 1 Diabetes
por: Xu, Ping, et al.
Publicado: (2014)

Recommendations for the Definition of Clinical Responder in Insulin Preservation Studies
por: Beam, Craig A., et al.
Publicado: (2014)

Modeling cell-mediated immunity in human type 1 diabetes by engineering autoreactive CD8(+) T cells
por: Peters, Leeana D., et al.
Publicado: (2023)

T cells display mitochondria hyperpolarization in human type 1 diabetes
por: Chen, Jing, et al.
Publicado: (2017)

Genetic Composition and Autoantibody Titers Model the Probability of Detecting C-Peptide Following Type 1 Diabetes Diagnosis
por: Williams, MacKenzie D., et al.
Publicado: (2021)

Development of Autoantibodies in the TrialNet Natural History Study
por: Vehik, Kendra, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_mgiol711mspqcotmb3f5s3df5i